Clinical Challenges to Current Molecularly Targeted Therapies in Lung Cancer.

Arch Cancer Res 2015;3(3)

Department of Biomedical Sciences, University of Illinois College of Medicine, Rockford, Illinois, USA.

Lung cancer is difficult to treat with a poor prognosis and a five year survival of 15%. Current molecularly targeted therapies are initially effective in non-small cell lung cancer (NSCLC) patients; however, they are plagued with difficulties including induced resistance and small therapeutically responsive populations. This mini review describes the mechanism of resistance to several molecularly targeted therapies which are currently being used to treat NSCLC. The major targets discussed are c-Met, EGFR, HER2, ALK, VEGFR, and BRAF. The first generation tyrosine kinase inhibitors (TKIs) resulted in resistance; however, second and third generation TKIs are being developed, which are generally more efficacious and have potential to treat NSCLC patients with resistance to first generation TKIs. Combination therapies could also be effective in preventing TKI resistance in NSCLC patients.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4894332PMC
http://dx.doi.org/10.21767/2254-6081.100030DOI Listing
January 2015
2 Reads

Publication Analysis

Top Keywords

lung cancer
12
molecularly targeted
12
nsclc patients
12
targeted therapies
12
generation tkis
8
treat nsclc
8
current molecularly
8
resistance
5
populations mini
4
developed generally
4
therapeutically responsive
4
responsive populations
4
mini review
4
describes mechanism
4
review describes
4
tkis developed
4
generally efficacious
4
resistance small
4
including induced
4
potential treat
4

Similar Publications